"Resistance mutations associated with AZT or d4T treatment accumulate at a relatively slow rate in people who remain on failing antiretroviral treatment for long periods, an analysis of the EuroSIDA cohort has shown.
"The study, published in the September 1st edition of the Journal of Infectious Diseases, show that once initial resistance to AZT or d4T develops (thymidine analogue resistance), the acquisition of further resistance mutations tends to be a slow process, with an average of one thymidine analogue mutation developing during 4.3 years of follow-up."
Read more in Aidsmap, September 8, 2009.
0 comments:
Post a Comment